Literature DB >> 1540221

Carrier-mediated uptake of pravastatin by rat hepatocytes in primary culture.

T Komai1, E Shigehara, T Tokui, T Koga, M Ishigami, C Kuroiwa, S Horiuchi.   

Abstract

The transport mechanism of pravastatin, a new cholesterol-lowering drug, was compared in vitro with rat hepatocyte primary culture and mouse skin fibroblasts (L-cells). The uptake of 14C-labeled pravastatin by cultured hepatocytes was temperature- and dose-dependent. The temperature-dependent uptake as a function of [14C]pravastatin concentration showed saturation kinetics with Km = 32.2 microM and a maximal uptake rate of 68 pmol/mg protein/min. The uptake of pravastatin was inhibited significantly by metabolic inhibitors such as rotenone, oligomycin A, antimycin A, 2,4-dinitrophenol and KCN. Unlabeled pravastatin as well as R-416 and R-195, structural analogues of pravastatin, effectively competed for the hepatic uptake of [14C]pravastatin at 37 degrees. These results indicate that pravastatin is taken up by the liver by an active transport. In contrast, the transport of pravastatin by L-cells was temperature-independent and non-saturable, suggesting that the uptake of pravastatin by L-cells is mediated by passive diffusion. The marked difference in the uptake mechanism of pravastatin between hepatocytes and L-cells may account for a unique feature of this drug in that the uptake and inhibition of cholesterol biosynthesis occur selectively in the liver.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1540221     DOI: 10.1016/0006-2952(92)90228-b

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  14 in total

1.  Pharmacokinetic and pharmacodynamic evaluation for tissue-selective inhibition of cholesterol synthesis by pravastatin.

Authors:  T Hatanaka; S Honda; S Sasaki; K Katayama; T Koizumi
Journal:  J Pharmacokinet Biopharm       Date:  1998-06

2.  Pravastatin, an HMG-CoA reductase inhibitor, is transported by rat organic anion transporting polypeptide, oatp2.

Authors:  T Tokui; D Nakai; R Nakagomi; H Yawo; T Abe; Y Sugiyama
Journal:  Pharm Res       Date:  1999-06       Impact factor: 4.200

3.  Inhibition of in vitro metabolism of simvastatin by itraconazole in humans and prediction of in vivo drug-drug interactions.

Authors:  M Ishigam; M Uchiyama; T Kondo; H Iwabuchi; S Inoue; W Takasaki; T Ikeda; T Komai; K Ito; Y Sugiyama
Journal:  Pharm Res       Date:  2001-05       Impact factor: 4.200

4.  Evaluation of the uptake of pravastatin by perfused rat liver and primary cultured rat hepatocytes.

Authors:  M Ishigami; T Tokui; T Komai; K Tsukahara; M Yamazaki; Y Sugiyama
Journal:  Pharm Res       Date:  1995-11       Impact factor: 4.200

Review 5.  Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events.

Authors:  T Hatanaka
Journal:  Clin Pharmacokinet       Date:  2000-12       Impact factor: 6.447

Review 6.  Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.

Authors:  H Lennernäs; G Fager
Journal:  Clin Pharmacokinet       Date:  1997-05       Impact factor: 6.447

7.  Co-administration of paroxetine and pravastatin causes deregulation of glucose homeostasis in diabetic rats via enhanced paroxetine exposure.

Authors:  Feng Li; Mian Zhang; Dan Xu; Can Liu; Ze-Yu Zhong; Ling-Ling Jia; Meng-Yue Hu; Yang Yang; Li Liu; Xiao-Dong Liu
Journal:  Acta Pharmacol Sin       Date:  2014-06       Impact factor: 6.150

8.  Cellular uptake of fluvastatin, an inhibitor of HMG-CoA reductase, by rat cultured hepatocytes and human aortic endothelial cells.

Authors:  M Ohtawa; N Masuda; I Akasaka; A Nakashima; K Ochiai; M Moriyasu
Journal:  Br J Clin Pharmacol       Date:  1999-04       Impact factor: 4.335

9.  Tissue-selective inhibition of sterol synthesis in mice by pravastatin sodium after a single or repeated oral administrations.

Authors:  T Koga; T Kikuchi; A Miyazaki; H Koike
Journal:  Lipids       Date:  1995-08       Impact factor: 1.880

10.  Disposition and metabolism of pravastatin sodium in rats, dogs and monkeys.

Authors:  T Komai; K Kawai; T Tokui; Y Tokui; C Kuroiwa; E Shigehara; M Tanaka
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Apr-Jun       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.